Daraxonrasib Nearly Doubles Survival in Advanced Pancreatic Cancer — First Drug to Directly Target RAS

Daraxonrasib , recently approved by the FDA, is the first drug to directly target RAS in pancreatic cancer and nearly doubled median overall survival in a phase 3 trial. In about 500 previously treated patients...



























